Sareum Ltd. Announces $5 Million Research Collaboration With Idenix Pharmaceuticals, Inc.

Sareum Holdings plc (AIM: SAR), the specialist structure-based drug discovery and services business, is pleased to announce that it has entered into a collaborative research agreement with Idenix Pharmaceuticals, Inc (Idenix) to discover novel hepatitis C compounds. Idenix is based in Cambridge, Mass, USA, and is engaged in the discovery, development and commercialization of innovative anti-viral therapeutics.